CANbridge Pharmaceuticals Data on CAN106, to be Presented at Two Conferences
Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Beijing, China; Cambridge, Mass., September, 22, 2022 — CANbridge Pharmaceuticals, Inc. (1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it will be presenting data from the CAN106 Phase 1 trial in healthy volunteers at two conferences. CAN106 is under development for paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases and is currently in a Phase 1b/2 study in patients with PNH in China.
The conferences are:
- 17th National Conference on Hematology (Shanghai)
Bing Han, MD, Chief Physician and Professor in the Department of Hematology, at the Peking Union Medical College Hospital, and principal investigator of the ongoing CAN106 Phase 1b/2 trial in PNH in China, will present CAN106 Phase 1 data.
Presentation on Saturday, September 24, 2022, at 4:05 PM CST
- 6th Annual Complement Based Drug Development Summit 2022 (Boston)
Gerry Cox, MD, Interim Chief Medical Officer, Chief Development Strategist, CANbridge Pharmaceuticals, will present CAN106 Phase 1 data.
Presentation on Wednesday, September 28, 2022, at 11:40 AM EST
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. (HKEX:1228) is a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School, the University of Washington School of Medicine, Scriptr Global and LogicBio.
For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
U.S. Investor Relations:
China Investor Relations
CANbridge Pharmaceuticals Inc.